HUP0500422A2 - Eljárás az akut mieloid leukémia indolin-származékokkal való kezelésére - Google Patents
Eljárás az akut mieloid leukémia indolin-származékokkal való kezeléséreInfo
- Publication number
- HUP0500422A2 HUP0500422A2 HU0500422A HUP0500422A HUP0500422A2 HU P0500422 A2 HUP0500422 A2 HU P0500422A2 HU 0500422 A HU0500422 A HU 0500422A HU P0500422 A HUP0500422 A HU P0500422A HU P0500422 A2 HUP0500422 A2 HU P0500422A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- heteroaryl
- aryl
- general formula
- alkyl
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title abstract 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title abstract 2
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000001072 heteroaryl group Chemical group 0.000 abstract 10
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000003277 amino group Chemical group 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 3
- 125000004434 sulfur atom Chemical group 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000006413 ring segment Chemical group 0.000 abstract 2
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Eljárás az akut mieloid leukémia kezelésére és az FLT-3 jelzésűtirozin kináz enzim foszforilezésének gátlására, amely abban áll, hogyegy ilyen kezelésre szoruló betegnek valamely (I) vagy (II) általánosképletű indolinonszármazéknak vagy sójának a hatás kifejtéséhezszükséges mennyiségét adagolják, ahol az (I) és (II) általánosképletben R jelentése hidrogénatom, hidroxilcsoport, alkilcsoport,arilcsoport, cikloalkilcsoport, heteroarilcsoport, alkoxicsoport,heterociklusos csoport vagy aminocsoport; R1 jelentése alkilcsoport,halogénatom, arilcsoport, alkoxicsoport, halogén-alkil-csoport,halogén-alkoxi-csoport, cikloalkilcsoport, heteroarilcsoport,heterociklusos csoport, hidroxilcsoport, vagy pedig -C(O)-R8, -NR9R10,-NR9C(O)-R12 vagy -C(O)NR9R10 általános képletű csoport; R2 jelentésealkilcsoport, arilcsoport, heteroarilcsoport, -C(O)-R3 vagy SO2R"általános képletű csoport, ahol R" jelentése alkilcsoport,arilcsoport, heteroarilcsoport, -NR9R10 általános képletű csoport vagyalkoxicsoport; R5 jelentése hidrogénatom, alkilcsoport, arilcsoport,halogén-alkil-csoport, cikloalkilcsoport, heteroarilcsoport,heterociklusos csoport, hidroxilcsoport, vagy pedig -C(O)-R8 vagy(CHR)rR11 általános képletű csoport; X jelentése oxigénatom vagykénatom; j jelentése 0 vagy 1; p jelentése 0, 1, 2 vagy 3; q jelentése0, 1 vagy 2; r jelentése 0, 1, 2 vagy 3; R8 jelentése hidroxilcsoport,alkilcsoport, arilcsoport, heteroarilcsoport, alkoxicsoport,cikloalkilcsoport vagy heterociklusos csoport; R9 és R10 jelentésehidrogénatom, alkilcsoport, arilcsoport, amino-alkil-csoport,heteroarilcsoport, cikloalkilcsoport és/vagy heterociklusos csoport,vagy R9 és R10 együtt, és a nitrogénatommal együtt gyűrűt képezhet,ahol a gyűrűatomok szénatomok, nitrogénatomok, oxigénatomok és/vagykénatomok lehetnek; R11 jelentése hidroxilcsoport, aminocsoport,egyszeresen vagy kétszeresen helyettesített aminocsoport,alkilcsoport, arilcsoport, heteroarilcsoport, alkoxicsoport,cikloalkilcsoport vagy heterociklusos csoport; R12 jelentésealkilcsoport, arilcsoport, heteroarilcsoport, alkoxicsoport,cikloalkilcsoport vagy heterociklusos csoport; Z jelentésehidroxilcsoport; alkoxicsoport; -NR3R4 általános képletű csoport, aholR3 és R4 jelentése egymástál függetlenül hidrogénatom, alkilcsoport,arilcsoport, heteroarilcsoport, cikloalkilcsoport és/vagyheterociklusos csoport, vagy R3 és R4 együtt, és a nitrogénatommalegyütt gyűrűt képezhet, ahol a gyűrűatomok helyén metiléncsoportok,nitrogénatomok, oxigénatomok és/vagy kénatomok lehetnek; vagy (a)általános képletű csoport, ahol Y jelentése előfordulási helyétőlfüggetlenül metiléncsoport, ox
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33062301P | 2001-10-26 | 2001-10-26 | |
PCT/US2002/034525 WO2003035009A2 (en) | 2001-10-26 | 2002-10-28 | Treatment of acute myeloid leukemia with indolinone compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0500422A2 true HUP0500422A2 (hu) | 2005-11-28 |
HUP0500422A3 HUP0500422A3 (en) | 2009-09-28 |
Family
ID=23290562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0500422A HUP0500422A3 (en) | 2001-10-26 | 2002-10-28 | Treatment of acute myeloid leukemia with indolinone compounds |
Country Status (19)
Country | Link |
---|---|
US (1) | US20030130280A1 (hu) |
EP (1) | EP1446117A4 (hu) |
JP (1) | JP2005511540A (hu) |
KR (1) | KR20040062591A (hu) |
CN (1) | CN101052394A (hu) |
AU (1) | AU2002360314B2 (hu) |
BR (1) | BR0213960A (hu) |
CA (1) | CA2464790A1 (hu) |
CZ (1) | CZ2004619A3 (hu) |
HU (1) | HUP0500422A3 (hu) |
IL (1) | IL161378A0 (hu) |
IS (1) | IS7222A (hu) |
MX (1) | MXPA04003853A (hu) |
NZ (1) | NZ532405A (hu) |
PL (1) | PL370553A1 (hu) |
TN (1) | TNSN04065A1 (hu) |
TW (1) | TWI259081B (hu) |
WO (1) | WO2003035009A2 (hu) |
ZA (1) | ZA200403091B (hu) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2475455A1 (en) | 2002-02-15 | 2003-08-28 | Pharmacia & Upjohn Company | Process for preparing indolinone derivatives |
US20050032871A1 (en) * | 2002-09-03 | 2005-02-10 | Sugen, Inc. | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors |
TW200418836A (en) † | 2002-09-10 | 2004-10-01 | Pharmacia Italia Spa | Formulations comprising an indolinone compound |
US7452913B2 (en) * | 2003-02-24 | 2008-11-18 | Pharmacia & Upjohn Company | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
KR20060058728A (ko) * | 2003-10-02 | 2006-05-30 | 파마시아 앤드 업존 캄파니 엘엘씨 | 피롤-치환된 인돌리논 화합물의 염 및 다형체 |
US20060009510A1 (en) * | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
MX2007014087A (es) * | 2005-05-12 | 2008-02-07 | Pfizer | Combinaciones y procedimientos para usar un compuesto de indolinona. |
US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
BRPI0616202A2 (pt) * | 2005-09-20 | 2011-06-14 | Pfizer Prod Inc | formas de dosagem e uso de um inibidor da tirosina quinase |
CA2621809A1 (en) * | 2005-09-22 | 2007-04-05 | The Scripps Research Institute | Alkoxy indolinone based protein kinase inhibitors |
NZ595182A (en) | 2005-10-18 | 2012-12-21 | Janssen Pharmaceutica Nv | Pharmaceutical uses of 4-cyano-1H-imidazole-2-carboxylic acid { 2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl} -amide |
EP1973910B1 (en) * | 2006-01-27 | 2013-06-26 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Pyrrolo[3,2-c]pyridine-4-one 2-indolinone protein kinase inhibitors |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
AU2007240437B2 (en) | 2006-04-20 | 2012-12-06 | Janssen Pharmaceutica N.V. | Heterocyclic compounds as inhibitors of c-fms kinase |
BRPI0710548B8 (pt) | 2006-04-20 | 2021-05-25 | Janssen Pharmaceutica Nv | inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica |
US8084621B2 (en) | 2006-12-04 | 2011-12-27 | Jiangsu Simcere Pharmaceutical R&D Co. Ltd. | 3-Pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives and uses thereof |
JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
EP2090306A1 (en) | 2008-02-13 | 2009-08-19 | Ratiopharm GmbH | Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
EP2113248A1 (en) | 2008-04-29 | 2009-11-04 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide |
US20100310668A1 (en) * | 2008-02-13 | 2010-12-09 | Ratiopharm Gmbh | Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide |
EP2098521A1 (en) | 2008-03-06 | 2009-09-09 | Ratiopharm GmbH | Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation |
WO2009157011A1 (en) | 2008-06-23 | 2009-12-30 | Natco Pharma Limited | Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt |
EP2138167A1 (en) * | 2008-06-24 | 2009-12-30 | ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
EP2181991A1 (en) * | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
EP2255792A1 (en) | 2009-05-20 | 2010-12-01 | Ratiopharm GmbH | Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide |
EP2264027A1 (en) | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
WO2011083124A1 (en) | 2010-01-05 | 2011-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flt3 receptor antagonists for the treatment or the prevention of pain disorders |
MX2012008083A (es) | 2010-01-12 | 2012-08-15 | Ab Science | Inhibidores de triazol y oxazol quinaza. |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
US10220020B2 (en) | 2010-12-23 | 2019-03-05 | Nektar Therapeutics | Polymer-des-ethyl sunitinib conjugates |
WO2012088529A1 (en) | 2010-12-23 | 2012-06-28 | Nektar Therapeutics | Polymer-sunitinib conjugates |
EP2882757B1 (en) | 2012-08-07 | 2016-10-05 | Janssen Pharmaceutica, N.V. | Process for the preparation of heterocyclic ester derivatives |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
TWI569799B (zh) | 2012-09-21 | 2017-02-11 | 安羅格製藥股份有限公司 | 抑制組成型活性磷酸化flt3激酶的方法 |
US10118918B2 (en) | 2012-12-21 | 2018-11-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
CA2894130A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
WO2014100695A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
PT2935222T (pt) | 2012-12-21 | 2018-12-10 | Epizyme Inc | Inibidores de prmt5 e seus usos |
CA2899363A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
BR112015016282A2 (pt) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
CN103274986A (zh) * | 2013-06-20 | 2013-09-04 | 湖南欧亚生物有限公司 | 一种舒尼替尼中间体的合成和精制方法 |
US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
CA2956417C (en) | 2014-07-31 | 2022-09-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Flt3 receptor antagonists |
AU2015301196A1 (en) | 2014-08-04 | 2017-01-12 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
CN106928114B (zh) * | 2015-12-31 | 2020-07-28 | 韶远科技(上海)有限公司 | 含有脲基的环状手性氨基类化合物及其可放大工艺和用途 |
EP3254698A1 (en) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
PE20191238A1 (es) | 2016-11-02 | 2019-09-11 | Arog Pharmaceuticals Inc | Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado |
CN111093640A (zh) | 2017-05-17 | 2020-05-01 | 国家健康与医学研究院 | 用于改善阿片类药物疼痛治疗的flt3抑制剂 |
WO2019057649A1 (en) | 2017-09-19 | 2019-03-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA |
WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
US11969420B2 (en) | 2020-10-30 | 2024-04-30 | Arog Pharmaceuticals, Inc. | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU759226B2 (en) * | 1998-05-29 | 2003-04-10 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
NZ519697A (en) * | 1999-12-22 | 2004-08-27 | Sugen Inc | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
CZ303705B6 (cs) * | 2000-02-15 | 2013-03-27 | Sugen, Inc. | Pyrrolem substituovaná 2-indolinonová sloucenina pro pouzití jako inhibitor proteinkináz a farmaceutická kompozice s jejím obsahem |
US6677368B2 (en) * | 2000-12-20 | 2004-01-13 | Sugen, Inc. | 4-aryl substituted indolinones |
AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
CA2462950A1 (en) * | 2001-10-10 | 2003-04-17 | Sugen, Inc. | 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors |
-
2002
- 2002-10-25 TW TW091125049A patent/TWI259081B/zh not_active IP Right Cessation
- 2002-10-28 AU AU2002360314A patent/AU2002360314B2/en not_active Ceased
- 2002-10-28 JP JP2003537578A patent/JP2005511540A/ja not_active Withdrawn
- 2002-10-28 CZ CZ2004619A patent/CZ2004619A3/cs unknown
- 2002-10-28 MX MXPA04003853A patent/MXPA04003853A/es not_active Application Discontinuation
- 2002-10-28 KR KR10-2004-7006222A patent/KR20040062591A/ko not_active Application Discontinuation
- 2002-10-28 BR BR0213960-0A patent/BR0213960A/pt not_active IP Right Cessation
- 2002-10-28 IL IL16137802A patent/IL161378A0/xx unknown
- 2002-10-28 PL PL02370553A patent/PL370553A1/xx not_active Application Discontinuation
- 2002-10-28 HU HU0500422A patent/HUP0500422A3/hu unknown
- 2002-10-28 CA CA002464790A patent/CA2464790A1/en not_active Abandoned
- 2002-10-28 WO PCT/US2002/034525 patent/WO2003035009A2/en active IP Right Grant
- 2002-10-28 CN CNA028229592A patent/CN101052394A/zh active Pending
- 2002-10-28 EP EP02795563A patent/EP1446117A4/en not_active Withdrawn
- 2002-10-28 US US10/281,266 patent/US20030130280A1/en not_active Abandoned
- 2002-10-28 NZ NZ532405A patent/NZ532405A/en unknown
-
2004
- 2004-04-15 IS IS7222A patent/IS7222A/is unknown
- 2004-04-16 TN TNP2004000065A patent/TNSN04065A1/en unknown
- 2004-04-22 ZA ZA200403091A patent/ZA200403091B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1446117A2 (en) | 2004-08-18 |
NZ532405A (en) | 2005-12-23 |
IL161378A0 (en) | 2004-09-27 |
CA2464790A1 (en) | 2003-05-01 |
JP2005511540A (ja) | 2005-04-28 |
AU2002360314B2 (en) | 2007-09-20 |
BR0213960A (pt) | 2004-08-31 |
IS7222A (is) | 2004-04-15 |
MXPA04003853A (es) | 2005-02-17 |
TNSN04065A1 (en) | 2006-06-01 |
PL370553A1 (en) | 2005-05-30 |
US20030130280A1 (en) | 2003-07-10 |
ZA200403091B (en) | 2005-01-14 |
KR20040062591A (ko) | 2004-07-07 |
EP1446117A4 (en) | 2008-01-23 |
CN101052394A (zh) | 2007-10-10 |
WO2003035009A2 (en) | 2003-05-01 |
HUP0500422A3 (en) | 2009-09-28 |
TWI259081B (en) | 2006-08-01 |
CZ2004619A3 (cs) | 2005-03-16 |
WO2003035009A3 (en) | 2004-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0500422A2 (hu) | Eljárás az akut mieloid leukémia indolin-származékokkal való kezelésére | |
HU9603578D0 (en) | Tri-substituted phenyl derivates useful as pde iv inhibitors | |
EA200000842A1 (ru) | Бицикло [2.2.1] гептаны и родственные соединения | |
HUP0400888A2 (hu) | Helyettesített ciklohexán-1,4-diamin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
TW200633990A (en) | Amide compound | |
UA95976C2 (en) | 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | |
UA95255C2 (en) | Azole and thiazole derivatives and their use | |
HUP0301382A2 (hu) | Alfa-aril-etanol-amin-származékok és e vegyületeket tartalmazó béta-3 adrenergiás receptor agonista hatású gyógyászati készítmények | |
ES2054826T3 (es) | Peptidos con actividad inhibidora de colagenasa. | |
ATE213735T1 (de) | Diaryldiamin derivate und ihre verwendung als agonisten/antagonisten des delta opioid rezeptors | |
TW200613297A (en) | Pyrazole derivatives | |
PE20021004A1 (es) | Derivados de piperidina como inhibidores de la ccr5 | |
MXPA04000494A (es) | Antagonistas del factor liberador de corticotropina hetero-biciclico. | |
HUP0004142A2 (hu) | 5-HT1F agonista hatású karboxamidszármazékok és a vegyületeket tartalmazó gyógyászati készítmények | |
YU43902A (sh) | Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže | |
MXPA04000371A (es) | 6- (2-tolil) - triazolopirimidinas substituidas. | |
UA84178C2 (en) | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones | |
ATE380810T1 (de) | Protein-tyrosine-kinase-inhibitoren | |
UA96120C2 (ru) | 1,3-пропандисульфонат стронция, способ его получения (варианты), его применение (варианты) и фармацевтическая композиция, содержащая его | |
UA90461C2 (en) | Pyrazole derivatives as protein kinase modulators | |
EA200200379A2 (ru) | Новые соединения пиримидин-4-она, способ их получения и содержащие их фармацевтические композиции | |
ES554054A0 (es) | Procedimiento para preparar piridin-1-oxidos varias veces substituidos | |
DE60103857D1 (de) | Verwendung von indoloquinoxalinen zur behandlung der multiplen sklerose | |
PL334624A1 (en) | Novel compounds of 8h-thiene-/2,3-b/pyrolysin-8-one, method of obtaining them and pharmaceutic compositions containing such compounds | |
TH77591A (th) | อนุพันธ์ 5-ฟีนิลไทอาโซล (5-phenylthiazole derivatives) และการใช้เป็นสารยับยั้ง PI3 ไคเนส (PI3 Kinase inhibitors) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |